Protocol Snapshot

Melanotan II Quick Reference

Verified Vendors

Melanotan II

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Loading Dose

0.25–0.5mg

Daily for 7 to 14 days in common community protocols.

Maintenance

2–3× weekly

Common community frequency after the desired pigmentation develops.

Class

Melanocortin Agonist

Review the full protocol details below.

Primary Effect

Pigmentation

Review the full protocol details below.

Peptide Grade

GradeC

Reliable tanning and libido reports make its effects noticeable, but nausea, pigmentation changes, spontaneous erections, and weak long-term safety data narrow the risk-reward profile.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What is Melanotan II?

Melanotan II , commonly written as MT-2 or MT2, is a synthetic cyclic peptide made of seven amino acids. It is an analog of alpha-melanocyte-stimulating hormone, or alpha-MSH, a naturally occurring signaling hormone involved in pigmentation and melanocortin receptor activity.

MT-2 was developed during research at the University of Arizona as investigators explored whether stimulating pigmentation could reduce the amount of ultraviolet exposure needed to produce a tan. The tanning effect was demonstrated in early human studies, but MT-2 was never approved as a medicine and is not regulated as a cosmetic tanning product.

What makes MT-2 unusual is that one compound can produce several noticeable effects at once: skin darkening, appetite reduction, nausea, flushing, yawning, and changes in sexual arousal or erectile activity. These effects arise because MT-2 is not selective for only one melanocortin receptor.

One Compound, Multiple Receptor Effects

MT-2 interacts with several melanocortin receptor pathways. MC1 is strongly associated with skin pigmentation, while central melanocortin signaling involving MC3 and MC4 contributes to appetite and sexual effects. Because the compound is non-selective, users cannot reliably separate the tanning effect from the other effects.

Bremelanotide, commonly called PT-141, was developed as a synthetic derivative intended to focus more on sexual-function effects. PT-141 later received FDA approval for a specific sexual desire disorder in premenopausal women. Melanotan II itself remains unapproved.

Melanotan II Benefits

The most established effects of MT-2 come from small early clinical studies and user reports. These effects should not be interpreted as proof of long-term safety.

Skin Darkening

Early human research demonstrated increased pigmentation after repeated MT-2 exposure. Users commonly report visible darkening during the first one to three weeks, although response varies substantially by baseline skin type.

Appetite Suppression

Reduced appetite has been observed in clinical research and is frequently reported by users. Any apparent fat-loss effect may result from lower calorie intake rather than a proven direct metabolic benefit.

Sexual Function Effects

Small clinical trials in men found increases in erectile activity and sexual desire. These effects can occur alongside nausea, yawning, appetite changes, and pigmentation.

Photoprotection Was the Original Goal

The original research concept was to increase melanin while reducing reliance on ultraviolet exposure. MT-2 has not been proven to prevent skin cancer, and a darker tan does not eliminate UV-related DNA damage.

UV Exposure Still Carries Risk: A deeper tan does not make intentional tanning safe. Ultraviolet exposure can still cause DNA damage, premature skin aging, and skin cancer.

Protocol Planning

Dosing, cycling, and preparation

Melanotan II Dosing Protocol

Melanotan II has no FDA-approved dosing protocol. The ranges below reflect community use rather than an established medical standard.

Loading Phase

Dose

0.25 to 0.5mg daily

Duration

7 to 14 days, or until the desired degree of pigmentation develops

Start Low

0.1 to 0.25mg is commonly used to assess nausea and flushing tolerance

Timing

Often taken before bed as a community strategy to reduce awareness of nausea

Route

Subcutaneous injection, commonly in the abdomen or thigh

Maintenance Phase

Dose

0.25 to 0.5mg

Frequency

2 to 3 times per week

Duration

Continued while pigmentation maintenance is desired

Community Use

Some users only dose around planned sun exposure, but UV exposure is not required for the drug to affect pigmentation

Timeline

Week 1–2 — Loading and Tolerance

Users commonly begin with a low dose to assess nausea, facial flushing, warmth, fatigue, and other acute effects. Some notice early skin darkening within several days. Appetite and sexual effects may appear within the first few doses.

Week 2–3 — Pigmentation Becomes More Visible

Skin darkening may become more pronounced. Existing moles and freckles can darken, and new pigmented spots may become noticeable. Any new or changing lesion should be assessed rather than assumed to be harmless.

Week 3+ — Maintenance

Community protocols commonly reduce dosing from daily use to two or three times weekly. Pigmentation gradually fades after discontinuation as skin cells turn over.

Skin Monitoring Matters: Darkening of moles and freckles can make visual monitoring more difficult. New, changing, asymmetric, irregular, multicolored, bleeding, or rapidly growing lesions should be evaluated by a dermatologist.

Melanotan II Reconstitution

The following example uses a common 10mg vial with 2mL of bacteriostatic water.

10mg Vial

Vial Size

10mg

BAC Water

2mL

Concentration

5mg/mL

0.25mg

5 units on a U-100 insulin syringe

0.5mg

10 units on a U-100 insulin syringe

Reconstitution Calculator

Handling Notes

Mixing

Add bacteriostatic water to the vial

Do Not

Do not shake aggressively

Storage

Refrigerate after reconstitution

Sterility

Online products may have uncertain identity, purity, potency, or sterility

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

Users frequently describe visible skin darkening during the first week, with deeper pigmentation developing over two to three weeks.
Sexual effects, including increased arousal or spontaneous erections, are commonly described as a noticeable secondary effect.
Reduced appetite is consistently reported, although intensity varies considerably.

Negative Reports

Nausea, facial flushing, warmth, fatigue, chills, and a flu-like feeling are common reasons users reduce the dose or discontinue use.
Darkening of moles, freckles, and injection sites concerns many users and can complicate visual skin monitoring.
Fair-skinned users who do not tan naturally often report weaker or less predictable pigmentation.

Stacking & Synergy

Potential Melanotan II pairings and tracking context

Melanotan II Stacking & Synergy

MT-2 + GLP-1 Agonists

MT-2 and GLP-1-based medications affect appetite through different receptor systems. There is little direct combination research, but appetite suppression may compound, increasing the risk of under-eating, dehydration, nausea, or difficulty meeting protein and micronutrient needs.

Avoid MT-2 + PT-141

PT-141 is a synthetic derivative of Melanotan II with overlapping melanocortin activity. Combining them is pharmacologically redundant and may increase nausea, flushing, blood-pressure effects, erections, or priapism risk.

Compounded Appetite Suppression: Using MT-2 with retatrutide, semaglutide, tirzepatide, or another appetite-suppressing drug may make it harder to maintain adequate food, fluid, and electrolyte intake.

Free with login

Track in Journal

Track Melanotan II with the markers that matter most for this compound.

Dose, timing, cumulative exposure, and cycle day.
Nausea, flushing, appetite, libido, and spontaneous erections.
Pigmentation response, freckles, moles, and other skin changes.

Start Tracking

Common Questions

Common questions about Melanotan II

How long does the tan last after I stop?

Pigmentation can persist for several weeks because melanin remains in skin cells until normal turnover occurs. Users commonly describe gradual fading over roughly four to eight weeks, although this varies by skin type, UV exposure, and the degree of pigmentation achieved.

Does MT-2 cause melanoma?

A direct causal link has not been established. However, case reports and observational concerns exist, MT-2 can darken existing lesions, and users may also intentionally increase UV exposure. Anyone with a personal or strong family history of melanoma, atypical moles, or suspicious lesions should avoid use and seek dermatology guidance.

Can I get the tanning effect without the sexual side effects?

Not reliably. MT-2 is non-selective and can produce pigmentation, appetite, nausea, and sexual effects together. Afamelanotide is more MC1-oriented, but it is a prescription implant used for erythropoietic protoporphyria rather than cosmetic tanning.

Do I need sun exposure for it to work?

No. Early research showed increased pigmentation without deliberate UV exposure. Additional UV exposure may deepen tanning, but it also adds the established risks of DNA damage, premature aging, and skin cancer.

Is injecting before bed a good strategy?

Bedtime dosing is a community practice rather than a medically established recommendation. Some users choose it because acute nausea, flushing, and warmth may occur soon after injection, but sleeping does not remove the underlying risk of an adverse reaction.

Why is MT-2 called the “Barbie peptide”?

It is a social-media nickname associated with the cosmetic tanning effect. The nickname can make the drug sound harmless, but MT-2 remains an unapproved injectable with uncertain product quality and potentially serious adverse effects.

Safety Notes

Side effects, contraindications, and precautions

Melanotan II Side Effects

Small clinical studies consistently reported acute effects such as nausea, facial flushing, yawning or stretching, appetite reduction, fatigue, and spontaneous erections. The frequency and intensity increased with dose in several studies.

Common and Dermatological Effects

Nausea, often beginning shortly after injection.
Facial flushing, warmth, yawning, or stretching.
Reduced appetite, fatigue, headache, chills, or stomach cramping.
Spontaneous erections or increased sexual arousal.
Darkening of moles, freckles, and sometimes the injection site.

Rare or Serious Risks

Priapism, which can cause permanent erectile damage if not treated urgently.
Rhabdomyolysis and acute kidney dysfunction described in case reports.
Renal infarction reported as a possible drug-associated event.
Severe vomiting, dehydration, chest symptoms, or neurologic symptoms require prompt medical evaluation.

Urgent Warning: An erection lasting four hours or longer is a medical emergency. Severe muscle pain, dark urine, reduced urination, chest pain, fainting, or severe vomiting also require urgent medical care.

Melanotan II Contraindications and Precautions

Do Not Use If You Have

A personal or strong family history of melanoma.
Active skin cancer or an untreated precancerous lesion.
Multiple atypical moles, dysplastic nevus syndrome, or an unexplained changing lesion.
Known hypersensitivity to Melanotan II or any component in the preparation.

Use Caution With

Pregnancy or breastfeeding, because no adequate safety data exists.
Cardiovascular disease or blood-pressure disorders.
Kidney disease, reduced kidney function, or a history of unexplained kidney injury.
Liver impairment.
A history of priapism or conditions that increase priapism risk.

Drug Interactions

Formal interaction studies are limited. Combining MT-2 with PT-141 may increase overlapping melanocortin effects. Combining it with GLP-1 medications or other appetite suppressants may worsen nausea or inadequate calorie and fluid intake. Use caution with drugs that affect blood pressure, erectile function, or hydration status.

Regulatory Status

Melanotan II is not FDA approved for tanning, weight loss, sexual function, or any other human use. Products marketed online as injectable tanning agents are unapproved drugs and may be manufactured without reliable quality control.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We pretty much hate Melanotan II. Admittedly it is popular in the bro science or gym bro world and it definitely tans you — in fact we think it changes your race (kidding) — but the side effect profile is terrible. Users have complained about violent or immediate vomiting, extreme nausea, and maybe not as much complaining about the random erections it can cause. Not to mention it even causes appetite suppression.

Comparing to MT-1, MT-2 is far more potent, does not require UV light exposure to trigger melanin, and has not been approved for medical use. Because of this potency and additional side effects (such as impacting other melanocortin receptors related to appetite and erections), MT-1 is the only variant that has received regulatory approval for treating photohypersensitivity. MT-2 does provide similar sun / UV protection to MT-1. As always the sun is good for you, but in moderation and you never want to get burned as that is actual skin damage.

Due to the potential link with skin cancers, this one is still a high avoid for us. If you want a tan, buy Melanotan-1 and go sunbathe for 20 minutes a day. In 3 days you’ll have a golden base tan.

We see no reason to choose MT-2 when MT-1 exists with far fewer sides. Potent, but the risks and discomfort simply aren’t worth it in our opinion. We strongly advise against it.